CVS Turnaround Gains Traction as Insurance Business Surges

What happened

CVS Health reported Q1 2026 results showing a sharp rebound in its insurance segment, which management described as 'exploding,' along with improved retail pharmacy market share, confirming that the turnaround initiated in 2025 is accelerating. The DeepValue Master Report had flagged near-term pressure from litigation but noted Health Care Benefits margins were improving; the latest quarter shows that improvement is now driving strong earnings growth. The enterprise-wide restructuring targeting >$500M in savings and the shift to transparent pricing models (TrueCost, CostVantage) are yielding tangible results, supporting margin expansion. However, PBM regulatory risk and litigation remain unresolved overhangs that could temper gains. At ~12x P/E, the stock offers an attractive risk/reward if the momentum continues.

Implication

Q1 2026 results validate the restructuring and pricing strategies, reinforcing the BUY case. Investors should watch for sustained insurance margin improvement and PBM regulatory developments. The stock remains undervalued if the turnaround sticks, but litigation and regulatory risks demand caution.

Thesis delta

The previous BUY thesis hinged on stabilization and gradual improvement; Q1 2026 shows acceleration, particularly in insurance, exceeding expectations. This shift from 'stabilization' to 'growth' increases confidence in 2026 EPS upside and supports a more bullish outlook. The main risk is that regulatory or litigation shocks could reverse the momentum.